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Abstract
Purpose: To compare immediate nephroureterectomy with delayed nephroureterectomy after a trial of nephron-
sparing endoscopic surgery in patients who were treated initially at our institution from 1996 to 2004 for upper
tract urothelial carcinoma. Patients were monitored for upper tract recurrences, metastases, cancer-specific and
overall survival. Survival outcomes and perioperative measurements were compared between treatment groups.
Results: Of 73 patients, 62 underwent immediate nephroureterectomy and 11 proceeded to nephroureterectomy
after failed endoscopic management. Mean follow-up for all patients was 58 months and 75 months for patients
who were alive at last follow-up. Patients treated initially with endoscopy averaged a surveillance procedure
every 3.7 months and had a median delay to nephroureterectomy of 10 months. Perioperative measurements at
time of nephroureterectomy did not differ between groups. Overall survival 5 years from initial resection in the
delayed group and from nephroureterectomy in the immediate group was 64% and 59%, respectively; the
corresponding 5-year cancer-specific and metastasis-free survival estimates were 91% vs 80% and 77% vs 73%,
respectively (P> 0.05). Pathologic progression from low to high-grade occurred in three of seven patients from
the delayed group.
Conclusions: Failure of endoscopic management necessitating nephroureterectomy does not appear to affect
survival outcomes compared with immediate nephroureterectomy in patients with upper tract urothelial car-
cinoma. A trial of endoscopic management can be considered in patients with low-grade disease and a normal
contralateral kidney. Endoscopy is a viable option when there are imperative indications for nephron sparing in
the setting of high-grade disease.
Introduction
Upper tract urothelial carcinoma (UTUC) is a raredisease, accounting for approximately 5% of all renal
and urothelial tumors.1 Radical nephroureterectomy (NUx)
with bladder cuff remains the gold-standard treatment.2 The
initial development and use of ureteroscopic3 and percuta-
neous4 techniques in UTUC provided reasonable alternatives
to NUx in patients with imperative indications for nephron
sparing.5 With further refinement and standardization of the
techniques, we and others have shown that endoscopic
management can be successfully applied to patients with a
normal contralateral kidney with limited low-grade disease.6–11
Despite this success, 19% to 33% of patients experience disease
progression necessitating NUx.6–11
We recently reported long-term results of endoscopic
management and hand-assisted laparoscopic (HAL) NUx in
96 renal units with UTUC.7 Of the 34 renal units with initial
endoscopic management, 11 (32%) later needed NUx. We
report on these patients who progressed to NUx after a trial of
nephron-sparing management, and exclusively compare
themwith patients who underwent immediate NUx. Our goal
is to elucidate whether patients who eventually progress to
NUx are adversely affected by the initial decision to pursue
endoscopic management of UTUC.
Patients and Methods
With Institutional Review Board approval, we identified 73
patients with clinically localized UTUC treated initially at our
institution from 1996 through 2004 who underwent NUx. A
subset of these patients initially underwent primary endo-
scopic management and delayed NUx. No patients received
neoadjuvant chemotherapy.
Endoscopy
All delayed NUx patients initially pursued endoscopic
management with curative intent. We initially used uretero-
scopy (URS) in most cases, as described previously.12 UTUC
was confirmed with biopsy in most cases and with cytology
from saline barbotage in the remaining. For tumors that could
not be completely ablated ureteroscopically, a percutaneous
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approach with a 24F resectoscope and flexible nephroscope
was used.
After initial successful tumor ablation, patients were
counseled regarding continued endoscopic management vs
NUx. UTUC grade, size, and multifocality were considered
along with the patient’s medical condition and indications for
nephron sparing. Patients were informed of the estimated
need for additional procedures with each approach, likeli-
hood of recurrences, disease progression, impact on renal
function, and overall quality of life. Patients who declined
endoscopic management were included in the immediate
NUx group. Those who pursued endoscopic management
were required to have complete endoscopic tumor resection
and agree to regular URS at variable intervals determined by
tumor characteristics and recurrence patterns.12 Tumor re-
currences were first managed with URS, but percutaneous
nephroscopy was used, if needed. After each recurrence, the
decision for continued endoscopic management vs proceed-
ing to NUx was reconsidered. When nephron-sparing man-
agement was abandoned, NUx was preferentially performed
with HAL surgery (HALS), when possible.
Immediate nephroureterectomy
Patients with initial disease not amendable to nephron-
sparing management and those who declined endoscopic
surveillance underwent NUx as described previously.13
Briefly, we used transperitoneal HALS with a variety of distal
ureter management techniques. Subsequent bladder surveil-
lance was first performed with flexible office cytoscopy at 3
months and then at variable intervals, depending on tumor
characteristics and recurrence patterns.
Systemic surveillance
Systemic surveillance was conducted in all patients every 6
to 12 months, depending on tumor characteristics and recur-
rence patterns, using abdominal-pelvic CT or MRI, plain ra-
diography, or CT chest imaging, and complete blood cell
count and complete serum chemistry.
Data analysis
The 1998 World Health Organization classification was
used for tumor grade assignment. Previous studies have
shown that endoscopic biopsy is accurate at determining
grade, thus allowing for initial disease classification in the
delayed patients.14,15 NUx specimens were pathologically
staged using the Tumor-Node-Metastasis system. Staging of
endoscopic biopsies was not conducted. For classification of
grade progression in patients with delayed NUx, pathologic
grade from initial endoscopic resection was compared with
final pathology determination at the time of NUx. Only pa-
tients with low-grade disease at initial resection were eligible
for grade progression. Patients with initial high-grade disease
were consideredmaximally progressed at diagnosis, and thus
excluded from this subset analysis. Preoperative medical re-
cords were used to gather patient data including age, sex,
body mass index, American Society of Anethesiologists score,
and any previous occurrence of bladder tumors before dis-
covery of UTUC. Age-adjusted Charlson comorbidity index
(CCI) excluding the diagnosis of urothelial carcinoma was
calculated.16
For survival measurements, the starting point was the date
of initial complete tumor resection, whether by endoscopy in
the delayed group or NUx in the immediate group. In the
delayed group, URS was used to determine local upper tract
recurrence. Event time for local recurrence and systemic
spread was defined as first documented date of recurrence or
metastasis. The last disease-free surveillance date determined
the censored time in patients without recurrence or metasta-
sis. Overall survival (OS) and cancer-specific survival (CSS)
data were obtained by contacting referring physicians, pa-
tients, and families, and by querying the University of Mi-
chigan Cancer Registry and the Social Security Death Index.
In most cases, death from UTUC vs other causes was deter-
mined from these data sources.
Intraoperative complications from both endoscopy and
NUx were recorded. Major intraoperative complications ne-
cessitated significant additional surgical or medical interven-
tion. Postoperative complications within 30 days and any later
complications directly related to the procedure were graded
with the modified Clavien classification system.17 For com-
parison of NUx operative data between study groups, only
patients who underwent the HALS technique were included.
Statistical analysis was performed with commercial soft-
ware. A P value< 0.05 was considered significant. For com-
parisons of demographic, pathologic, and operative data
between study groups, we used the Mann-Whitney U test for
continuous variables and chi-square or Fisher exact test for
categorical variables. Survival estimates were obtained from
Kaplan-Meier curves, and the survival data were compared
with the log-rank test.
Results
Of the 73 patients in our study, 11 patients were initially
treated with endoscopy, and 62 proceeded directly to NUx.
Mean follow-up from initial complete resection in delayed
and immediate groups was 61 months and 58 months, re-
spectively. Patient demographics and NUx pathologic data
are shown in Table 1. Demographic data are from the time of
NUx except for a history of bladder tumors. While signifi-
cance was not obtained, patients in the delayed group tended
to be older and had a greater CCI than patients in the im-
mediate group (Table 1). From the time of initial complete
resection, delayed NUx patients also tended to be older than
immediate NUx patients (mean= 73– 5.9 years, P= 0.2174)
and had greater CCI (mean= 3.9 – 1.0, P = 0.2321). A signifi-
cantly greater percentage of delayed NUx patients previously
had bladder tumors (Table 1).
Pathologic NUx data did not reveal significant differences
in tumor size, grade, extent, location, or staging, although
there was trend to larger tumors in the immediate NUx pa-
tients (Table 1). At the time of initial endoscopic biopsy, 7/10
(70%) delayed NUx patients had low-grade disease, not sig-
nificantly different from immediate NUx patients (45%,
P = 0.1835). Of these initial seven patients with low-grade
disease, progression to high-grade disease occurred in three
(43%) at the time of delayed NUx. At diagnosis, disease was
confined to the renal pelvis for all patients in the delayed
group, but at NUx, disease was found in both renal pelvis and
ureter in 7/11 (64%).
Table 2 displays individual delayed NUx patient data. Of
11 patients, 5 (46%) pursued endoscopic treatment electively.
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Of the remaining six patients, one had chronic renal insuffi-
ciency (CRI) with a preoperative creatinine level of 2.5mg/
dL, one had relative CRI with a creatinine level of 1.6mg/dL,
two had solitary kidneys (previous nephrectomy for cancer),
and two presented with bilateral UTUC.
Initial complete tumor resection for the 11 delayed NUx
patients was obtained with 16 procedures (9 URS, 7 percuta-
neous). There were no complications during or after these
procedures. Of all the delayed patients, eight entered sur-
veillance at our institution and three with the referring urol-
ogist. Of the latter three, one was treated with mitomycin
instillation via nephrostomy tube after initial resection in an
attempt to increase the length of time between minimally in-
vasive surveillance procedures, given the patient’s poor
overall health. The intervening procedures before NUx are
unknown in the other two patients followed outside our in-
stitution. Of the eight patients we followed directly, there
were 42 subsequent operations (37 URS, 5 percutaneous). On
average, these eight patients underwent an operation every
3.7 – 1.0monthswhile on active surveillance. Therewere three
postoperative complications after surveillance procedures:
One grade IVb and two grade IIIb; all occurred in patient 3
(Table 2).
For delayed NUx patients, median time to disease recur-
rence was 4.0 months, and median time to NUx was 10
months. After the first surveillance procedure, 5/11 (46%)
Table 1. Demographics and Tumor Characteristics at Nephroureterectomy, by Treatment Group
Variable (no. in group) Delayed nephroureterectomy Immediate nephroureterectomy P value
All renal units (73) 11 62
Sex
Male (52) 10 (91%) 42 (68%) 0.1602
Female (21) 1 (9%) 20 (32%)
Age, years (mean – SD) 74.9 – 5.4 69.0 – 10.6 0.0688
BMI (mean– SD) 27.0 – 3.6 28.5 – 5.5 0.5073
< 30, nonobese (47) 8 (73%) 39 (63%) 0.6887
30–40, obese (23) 3 (27%) 20 (32%)
> 40, morbidly obese (3) 0 (0%) 3 (5%)
ASA score (mean– SD) 2.5 – 0.5 2.2 – 0.6 0.3125
ASA 1–2 (49) 6 (54.5%) 43 (69%) 0.4870
ASA 3–4 (24) 5 (45.5%) 19 (31%)
Age-adjusted CCI (mean – SD) 4.2 – 1.3 3.4 – 1.8 0.1245
0 - 3 (38) 4 (36%) 34 (55%) 0.3335
‡ 4 (35) 7 (64%) 28 (45%)
History of bladder tumors
No previous bladder tumors (57) 4 (36%) 53 (85.5%) 0.0014
Previous bladder tumors (16) 7 (64%) 9 (14.5%)
Pathology
Greatest tumor diametera
< 2 cm, small (12) 4 (40%) 8 (13%) 0.0607
‡ 2 cm, large (58) 6 (60%) 52 (87%)
Gradea
Low (32)b 4 (40%) 28 (45%) 0.9999
High (40) 6 (60%) 34 (55%)
Extent
Solitary (35) 2 (20%) 33 (53%) 0.0861
Multifocal (37) 8 (80%) 29 (47%)
Location
Renal pelvis (64)c 10 (100%) 54 (87%) 0.5891
Ureter (8) 0 (0.0%) 8 (13%)
T stage
T0 (5) 1 (9.1%) 4 (6.5%) 0.3021
Ta (35) 3 (27%) 32 (52%)
Tis (2) 1 (9.1%) 1 (1.6%)
T1 (9) 3 (27%) 6 (9.7%)
T2 (3) 0 3 (4.8%)
T3 (19) 3 (27%) 16 (26%)
N stage
0 (68)d 9 (100%) 59 (95%) p = 0.9999
1 (3) 0 3 (5%)
Data expressed as mean– standard deviation for continuous data, or No. in group (%) for nominal data.
aSome data elements missing. For patients with T0, grade from initial biopsy is reported.
bOne patient in immediate NUx treatment group had a pathologic grade of LMP.
cSeven delayed NUx and nine immediate NUx patients with renal pelvic tumors also had ureteral tumors.
dTwo patients in the delayed group did not have sufficient lymph node dissection for N staging.
SD= standard deviation; BMI – body mass index; ASA=American society of anesthesiologists; CCI=Charlson comorbidity index;
T= tumor; N =node.
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patients proceeded to NUx. Table 2 lists the reasons for pro-
ceeding to NUx. There was high volume recurrence in five
patients at concern for significant risk of future progression,
and endoscopically unresectable recurrence in five patients.
Patient 7 underwent open NUx at an outside institution;
whether the surgery was elective or for disease progression is
unknown. Two patients (3 and 11, Table 2) underwent cy-
stoprostatectomy for recurrent bladder disease during the
same operation as NUx for unresectable UTUC. One of these
operations was performed with a laparoscopic technique, the
other with an open operation. The decision to proceed with
open surgery reflected the operating urologist’s preference
rather than the history of multiple endoscopic procedures.
Table 3 compares perioperative parameters of NUx per-
formed at our institution (without cystoprostatectomy) be-
tween eight delayed NUx patients and all immediate NUx
patients. There were no significant differences in operative
time, estimated blood loss, length of hospital stay, or com-
plication rates between the two groups. Delayed NUx in-
traoperative complications included minor lacerations of the
diaphragm in one patient and liver in one patient, both re-
paired without difficulty. One major complication of damage
to the contralateral ureteral orifice necessitated significant
surgical intervention to repair. ImmediateNUx intraoperative
complications included five minor small bowel lacerations
with simple repairs, one major small bowel laceration necessi-
tating open repair, and 1 major spleen laceration necessitating
cautery repair. Clavien graded postoperative complications for
both groups are listed in Table 3.
Figure 1 displays Kaplan-Meier survival curves that com-
pare treatment groups. There was no significant difference in
OS from date of first complete resection (Fig. 1A) with 5-year
survivals in the delayed and immediate group of 64% and
59%, respectively. No significant differences were found in
the 5-year metastasis-free survivals from initial treatment for
delayed and immediate NUx, 77% and 73%, respectively (Fig.
1B), and of CSS, 91% and 80%, respectively (Fig. 1C).
Discussion
We and others showed previously that conservative man-
agement for low-grade UTUC is equivalent to immediate
NUx when patients are grouped by initial treatment meth-
ods.7–9 This current report suggests that failed conservative
management does not significantly affect survival, compared
with immediate NUx, when appropriate triggers for delayed
NUx are applied.
Similar studies that compare patients with delay to ex-
tirpative surgery are relatively rare in the current literature, and
often there is substantial heterogeneity in the treatment meth-
ods between initial diagnosis and definitive resection. Most
analogous to our study, Boorjian and associates18 reported on
12 patients with low-grade disease and found that a mean
delay of 196 days (6.5 mos) to NUx after ureteroscopic biopsy
and laser ablation did not adversely affect disease status at a
mean follow-up of 38.7 months compared with patients who
had immediate NUx. Sundi and colleagues19 recently com-
pared 54 patients who delayed surgical management of UTUC
more than 3 months from diagnosis with 186 patients who
underwent surgery less than 3 months from diagnosis; 94% of
procedures were NUx, with a mean time to surgery in the
delayed group of 14.4 months. Of the delayed group, 50%
underwent neoadjuvant chemotherapy, 17% (nine patients)
delayed NUx for endoscopic management, and the remaining
patients were delayed by referral time and patient comorbid-
ities. High-grade disease was found in approximately 80% of
both groups, yet therewas no significant difference betweenOS
or CSS when all patients were compared. More relevant to our
study, no difference was found in OS or CSS when patients
receiving neoadjuvant chemotherapy were excluded.
Table 3. Laparoscopic Nephroureterectomy Operations
Variable (no.)
Delayed
nephroureterectomy{
Immediate
nephroureterectomy P value
Operative time in minutes (8 delayed,
60 immediate)
278 – 130 (range, 127–551;
median, 235)
253 – 72 (range, 117–457;
median, 246)
0.9242
Estimated blood loss in mL (8 delayed, 57 immediate) 231 – 180 (range, 50 –500;
median, 188)
284– 241 (range, 50–1400;
median, 200)
0.5491
Length of hospital stay in days (8 delayed,
62 immediate)
6 – 6 (range, 2 – 21;
median 4)
4 – 3 (range, 1–17;
median, 4)
0.7327
Patients with intraoperative complications (8 delayed,
62 immediate)
3 (38%) 7 (11%) 0.0812
Patients with postoperative complications (8 delayed,
62 immediate)
3 (38%) 18 (29%) 0.6889
Patients with any complications (8 delayed, 62 immediate) 5 (63%) 22 (36%) 0.2457
Clavien grade postoperative complications (8 delayed,
62 immediate)
0.0699
I 0 11 (18%)
II 1 (13%) 3 (5%)
IIIa 0 1 (2%)
IIIb 1 (13%) 1 (2%)
IVa 1 (13%) 0
IVb 0 1 (2%)
Data expressed as mean– standard deviation for continuous data (range; median), or no. in group (%) for nominal data.
{Data from 2 patients who underwent nephroureterectomy with cystoprostatectomy, and from 1 patient who underwent
nephroureterectomy at an outside institution, are excluded.
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Waldert and coworkers20 compared 41 patients, of whom
only 7 had previous endoscopic procedures, who delayed
NUxmore than 3months (median 110 days) with 146 patients
who underwent NUx within 3 months of UTUC diagnosis.
High-grade disease was found in 64% and 76% of immediate
and delayed groups, respectively. CSS did not differ with
delayed NUx, despite an increase in pathologic T stage and
lymph node involvement.
While the heterogeneity of these studies makes specific
comparisons challenging, these reports are consistent with
our findings that a trial of endoscopic management does not
worsen survival in patients with UTUC.
Our results and those of others are critical in determining
the relative safety of attempting endoscopic management,
especially in light of the reported risks of delaying cystectomy
in patients with clinical stage T2 or higher bladder cancer.
21,22
In two studies, OS was significantly worse when patients
delayed surgerymore than 3months from diagnosis, and CSS
was worse in one study. Most endoscopically treated UTUC
patients are similar to pTa bladder cancer patients, where
superficial disease can frequently be treated effectively by
transurethral resection, reserving extirpative surgery (cy-
stectomy) for patients with invasive disease progression. The
previously mentioned studies of Sundi and associates19 and
Waldert and colleagues20 both reported a majority of patients
with high-grade disease in both delayed and immediate
groups. While the heterogeneity of the UTUC groups makes
comparisons less precise than in the bladder cancer studies,
these results may suggest that there is less of an impact to
delay in UTUC. There is likely a selection bias toward less
aggressive disease in delayed definitive management, how-
ever, despite high-grade pathology.
It is notable that while survival outcomes appear to be
equivalent in delayed extirpative surgery, pathologic up-
grading does occur in some patients. In our study, 3/7 pa-
tients experienced progression from low- to high-grade
carcinoma. In other studies, 33% of 12 patients18 and 71% of 7
patients8 progressed from low- to high-grade disease on NUx
after initial endoscopic management. Because endoscopic
management failed for these patients, there is a bias toward
more aggressive disease; however, the possibility of disease
progression must be accepted when patients elect conserva-
tive management.23
Patients must also be willing to undergo frequent mini-
mally invasive procedures during conservative management,
but no differences were found in perioperative parameters
and postoperative courses when HALS NUx is delayed. In a
large study of 6078 NUx performed for nonmetastatic UTUC,
Jeldres and coworkers24 found a 90-day perioperative mor-
tality of 4.4% in patients of all ages, 4.4% in patients 70 to 79
years old, and 8.3% in patients > 80 years; the most common
cause of death was renal insufficiency (45%). NUx techniques
were not reported, but given the nonstandardized NUx
method in UTUC, this statistic is critical when elderly patients
select disease management. Similar large population statistics
for endoscopic procedures were not found in the current lit-
erature; however, they are anecdotally considered safer re-
garding perioperative mortality.
Our report’s limitations include those intrinsic to retro-
spective studies. Nonrandomized patients and bias toward
small low-grade disease in patients who elected trials of en-
doscopic management are possible confounding factors. The
FIG. 1. Survival curves that compare immediate with
delayed nephroureterectomy. Overall survival from first
complete resection (A), metastasis-free survival (B), and
cancer-specific survival (C). Five-year survival estimates in-
dicated by arrows. Curves were truncated when two or
fewer patients were at risk. Cum = cumulative
6 GADZINSKI ET AL.
delayed group was also limited in size and heterogeneous in
reasons for nephron-sparing management. The small size of
the delayed group prohibited meaningful multivariate anal-
ysis, and limits the power of our study. To our knowledge,
however, we are one of the first to report long-term outcomes
exclusively comparing patients who failed endoscopic man-
agement with those who underwent immediate NUx for
UTUC. The homogeneity of treatment method before defini-
tive surgery, despite heterogeneity in patient population, is a
strong point of this report.
There is increasing evidence that nephron-sparing man-
agement of low-grade UTUC is at worst equivalent to im-
mediate NUx.7–9 We have shown that failing endoscopic
management and proceeding to NUx does not affect OS and
cancer-related outcomes. Large multicenter prospective trials
with standardized protocols must be performed to confirm
that there is no harm in electing endoscopic therapy, and to
establish common practices guidelines for UTUC treatment.
Until then, it is our experience that patients with small low-
grade disease may elect a trial of conservative management
knowing that if disease progression necessitates NUx, sys-
temic long-term cancer progression and OS will not be ad-
versely affected.
Conclusions
Our study suggests that long-term OS and cancer-related
outcomes do not differ when patients attempt a trial of
endoscopy and delay NUx for UTUC. In cases of resectable
low-grade disease, initiating endoscopic monitoring is an
alternative to immediate NUx. We still hold that high-grade
disease should undergo immediate extirpative resection
when there are no indications for nephron sparing, but en-
doscopy can temporarily maintain the renal unit in patients
with imperative indications.
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Abbreviations Used
CCI¼Charlson comorbidity index
CRI¼ chronic renal insufficiency
CSS¼ cancer-specific survival
CT¼ computed tomography
HAL¼hand-assisted laparoscopic
HALS¼hand-assisted laparoscopic surgery
MRI¼magnetic resonance imaging
NUx¼nephroureterectomy
OS¼ overall survival
URS¼ureteroscopy
UTUC¼upper tract urothelial carcinoma
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